Show Summary Details
Page of

Cancer prevention: Vaccination 

Cancer prevention: Vaccination
Cancer prevention: Vaccination

Sarah E.B. Goltz

and Julian Lob-Levyt



Includes updated mortality figures for Hepatitis B and cervical cancer

States the current number of countries that have introduced HPV vaccine

Also covers the approval of Gardasil 9 in Europe

Updated on 25 May 2017. The previous version of this content can be found here.
Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 07 July 2020

This chapter describes the increasingly critical role of cancer vaccines in preventing, and potentially even treating, cancers in all resource settings. At this time, there are three cancer vaccines, two of which protect against cancer-causing viruses—hepatitis B virus (HBV) and the human papillomavirus (HPV); the third is an immunostimulant treatment virus for late-stage prostate cancer. Few advances in medicine and public health have had as substantial an impact on morbidity and mortality worldwide as vaccines. The potential public health impact of cancer vaccines is particularly significant in developing countries, where limited resources make prevention, screening, and disease management especially challenging. Numerous strategies are being employed to improve access to cancer vaccines in low- and middle-income settings. These efforts are beginning to demonstrate impact on cancer rates, indicating how innovative mechanisms may be used to expand access to HPV and other future cancer vaccines in the decades to come.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.